103 related articles for article (PubMed ID: 10435686)
1. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766).
Hoppe JE
J Chemother; 1999 Jun; 11(3):220-1. PubMed ID: 10435686
[No Abstract] [Full Text] [Related]
2. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Cynamon MH; Klemens SP; Sharpe CA; Chase S
Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
[TBL] [Abstract][Full Text] [Related]
3. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.
Dresser LD; Rybak MJ
Pharmacotherapy; 1998; 18(3):456-62. PubMed ID: 9620097
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Bordetella pertussis and Bordetella parapertussis to 24 antibiotics.
Hoppe JE; Haug A; Botzenhart K
Chemotherapy; 1987; 33(4):250-4. PubMed ID: 2886295
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.
Hoppe JE; Simon CG
Antimicrob Agents Chemother; 1990 Nov; 34(11):2287-8. PubMed ID: 2073123
[TBL] [Abstract][Full Text] [Related]
6. Linezolid approval brings new treatment option for resistant bacteria.
Am J Health Syst Pharm; 2000 Jun; 57(11):1018. PubMed ID: 10876739
[No Abstract] [Full Text] [Related]
7. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin.
Noskin GA; Siddiqui F; Stosor V; Kruzynski J; Peterson LR
Clin Infect Dis; 1999 Mar; 28(3):689-90. PubMed ID: 10194104
[No Abstract] [Full Text] [Related]
8. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Hoppe JE; Dalhoff A; Pfründer D
Antimicrob Agents Chemother; 1998 Jul; 42(7):1868. PubMed ID: 9661039
[No Abstract] [Full Text] [Related]
9. A novel antimicrobial agent joins the battle against resistant bacteria.
Moellering RC
Ann Intern Med; 1999 Jan; 130(2):155-7. PubMed ID: 10068364
[No Abstract] [Full Text] [Related]
10. [Bordetella pertussis and parapertussis. A comparison of the effects of chloramphenicol and other antibiotics in vitro].
Výmola F; Jedlicková Z; Buriánová-Vysoká B
Cesk Epidemiol Mikrobiol Imunol; 1966 Sep; 15(5):270-4. PubMed ID: 4292263
[No Abstract] [Full Text] [Related]
11. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins.
Hoppe JE; Müller J
Antimicrob Agents Chemother; 1990 Jul; 34(7):1442-3. PubMed ID: 2386374
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.
Hoppe JE; Rahimi-Galougahi E; Seibert G
Antimicrob Agents Chemother; 1996 Mar; 40(3):807-8. PubMed ID: 8851619
[TBL] [Abstract][Full Text] [Related]
13. [Susceptibility to macrolide antibiotics of Bordetella pertussis and Bordetella parapertussis strains isolated from whooping cough patients in 1968 and in 1997-99].
Chodorowska M; Kuklińska D; Tyski S
Med Dosw Mikrobiol; 2001; 53(1):39-43. PubMed ID: 11757403
[TBL] [Abstract][Full Text] [Related]
14. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.
Hoppe JE; Eichhorn A
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):653-4. PubMed ID: 2550234
[TBL] [Abstract][Full Text] [Related]
15. MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.
Bowersock TL; Salmon SA; Portis ES; Prescott JF; Robison DA; Ford CW; Watts JL
Antimicrob Agents Chemother; 2000 May; 44(5):1367-9. PubMed ID: 10770781
[TBL] [Abstract][Full Text] [Related]
16. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid.
Schaadt RD; Batts DH; Daley-Yates PT; Pawsey SD; Stalker DJ; Zurenko GE
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):201-4. PubMed ID: 9327249
[TBL] [Abstract][Full Text] [Related]
17. An update on the oxazolidinone antibiotics.
Abdel-Rahman SM; Kearns GL
Pediatr Infect Dis J; 1999 Dec; 18(12):1101-2. PubMed ID: 10608633
[No Abstract] [Full Text] [Related]
18. Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
D'Andrea S; Zheng ZB; Denbleyker K; Fung-Tomc JC; Yang H; Clark J; Taylor D; Bronson J
Bioorg Med Chem Lett; 2005 Jun; 15(11):2834-9. PubMed ID: 15911264
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis.
Mortensen JE; Rodgers GL
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():47-9. PubMed ID: 10824032
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.
Shinabarger DL; Marotti KR; Murray RW; Lin AH; Melchior EP; Swaney SM; Dunyak DS; Demyan WF; Buysse JM
Antimicrob Agents Chemother; 1997 Oct; 41(10):2132-6. PubMed ID: 9333037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
